CHO Pharma, Inc. (TPEX:6586)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
26.50
+0.05 (0.19%)
Feb 11, 2026, 1:53 PM CST

CHO Pharma Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
3.213.58-0.063.570.14
Revenue Growth (YoY)
196.67%---98.32%2486.96%-53.53%
Cost of Revenue
1.551.87-00.210.07
Gross Profit
1.661.71-0.063.360.07
Selling, General & Admin
34.7831.9329.6124.8620.3521.74
Research & Development
234.85219.08239.39326.1193.51287.88
Operating Expenses
269.62251269350.96213.85309.62
Operating Income
-267.96-249.29-269-350.9-210.49-309.56
Interest Expense
-0.54-0.68-0.08-0.3-0.58-0.78
Interest & Investment Income
37.8437.6816.247.055.468.11
Currency Exchange Gain (Loss)
0.290.07-0.53-0.130.220.18
Other Non Operating Income (Expenses)
--0.015.885.465.29
EBT Excluding Unusual Items
-230.38-212.23-253.36-338.39-199.93-296.75
Gain (Loss) on Sale of Assets
------0.09
Asset Writedown
---52.73--6-
Pretax Income
-230.38-212.23-306.09-338.39-205.93-296.84
Net Income
-230.38-212.23-306.09-338.39-205.93-296.84
Net Income to Common
-230.38-212.23-306.09-338.39-205.93-296.84
Shares Outstanding (Basic)
214214191184184184
Shares Outstanding (Diluted)
214214191184184184
Shares Change (YoY)
3.72%11.86%4.00%0.04%0.12%0.36%
EPS (Basic)
-1.08-0.99-1.60-1.84-1.12-1.62
EPS (Diluted)
-1.08-0.99-1.60-1.84-1.12-1.62
Free Cash Flow
-248.37-222.87-293.13-258.9-196.11-267.89
Free Cash Flow Per Share
-1.16-1.04-1.53-1.41-1.07-1.46
Gross Margin
51.84%47.77%-98.33%94.09%48.55%
Operating Margin
-8347.66%-6963.49%--584833.33%-5896.11%-224315.94%
Profit Margin
-7176.79%-5928.10%--563988.33%-5768.21%-215100.73%
Free Cash Flow Margin
-7737.35%-6225.53%--431501.67%-5493.25%-194121.74%
EBITDA
-255.98-237.71-250.3-324.67-184.88-282
D&A For EBITDA
11.9811.5918.726.2325.6127.56
EBIT
-267.96-249.29-269-350.9-210.49-309.56
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.